In three people with glaucoma, a single eye injection of the OSK-based gene therapy produced no serious safety signals through Day 56, the company said, and two showed visual field gains in an open-label test.
A placebo-controlled trial in 145 older adults with glucose intolerance found metformin slowed a deficit-based frailty index, but not the Fried frailty score, and shifted two of 13 epigenetic clocks.
